Tag: #Global Trends

Regulators demand further evidence of relacorilant’s clinical efficacy before granting market authorization. As 2025 drew to a close, the U.S.... Read more

The Supreme Court's ruling in Beijing bolsters the Danish pharmaceutical firm's position against rivals and generic alternatives. In a landmark... Read more

The French biotech firm has ended its cooperation with the world’s largest vaccine manufacturer to gain direct oversight of its... Read more

On the first day of 2026, the biotechnology firm Enveric Biosciences announced the issuance of a new US patent for... Read more

In late 2025, the pharmaceutical landscape saw a strategic shift as Emmaus Life Sciences officially transferred the commercial rights of... Read more

Strategic price cuts to bolster market dominance The Danish pharmaceutical giant Novo Nordisk has significantly reduced the price of its... Read more

Unexpected setback from the U.S. regulator In a surprising turn of events, Sanofi received a Complete Response Letter (CRL) from... Read more

Efficacy shortfall in DUPLEX-AD study Johnson & Johnson (J&J) has decided to halt the Phase 2 clinical trial of its... Read more

Synergy between G4 Stabilizer and leading ADC technology Senhwa Biosciences has reached a clinical milestone by initiating a Phase 1b... Read more